The Bob Harrington Show - Episode 45: Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega

Summary: The issue of clopidogrel genomics and CYP2C19 genotyping came to a head with the recent JAMA meta-analysis that questioned the use of clopidogrel loss-of-function gene testing—controversially stating that there is no link between genotype and cardiovascular events. Dr Jessica Mega joins the show to shine light on the rapidly evolving field of clopidogrel pharmacogenomics, examine the scientific data—and the controversy—and share her recommendations for practitioners.